SANN Statistics
Total Valuation
Santhera Pharmaceuticals Holding AG has a market cap or net worth of CHF 108.88 million. The enterprise value is 100.06 million.
Market Cap | 108.88M |
Enterprise Value | 100.06M |
Important Dates
The next estimated earnings date is Thursday, September 12, 2024.
Earnings Date | Sep 12, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Santhera Pharmaceuticals Holding AG has 11.72 million shares outstanding. The number of shares has increased by 0.42% in one year.
Shares Outstanding | 11.72M |
Shares Change (YoY) | +0.42% |
Shares Change (QoQ) | -11.82% |
Owned by Insiders (%) | 0.48% |
Owned by Institutions (%) | 11.07% |
Float | 8.67M |
Valuation Ratios
The trailing PE ratio is 1.85.
PE Ratio | 1.85 |
Forward PE | n/a |
PS Ratio | 0.95 |
PB Ratio | 1.75 |
P/FCF Ratio | 2.31 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.85, with an EV/FCF ratio of 2.12.
EV / Earnings | 1.83 |
EV / Sales | 0.97 |
EV / EBITDA | 1.85 |
EV / EBIT | 1.96 |
EV / FCF | 2.12 |
Financial Position
The company has a current ratio of 0.78, with a Debt / Equity ratio of 35.95.
Current Ratio | 0.78 |
Quick Ratio | 0.73 |
Debt / Equity | 35.95 |
Debt / EBITDA | 0.40 |
Debt / FCF | 0.46 |
Interest Coverage | 2.40 |
Financial Efficiency
Return on equity (ROE) is 673.95% and return on invested capital (ROIC) is 77.76%.
Return on Equity (ROE) | 673.95% |
Return on Assets (ROA) | 36.89% |
Return on Capital (ROIC) | 77.76% |
Revenue Per Employee | 2.30M |
Profits Per Employee | 1.22M |
Employee Count | 45 |
Asset Turnover | 1.19 |
Inventory Turnover | 3.37 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +8.64% in the last 52 weeks. The beta is 0.12, so Santhera Pharmaceuticals Holding AG's price volatility has been lower than the market average.
Beta (5Y) | 0.12 |
52-Week Price Change | +8.64% |
50-Day Moving Average | 8.86 |
200-Day Moving Average | 9.47 |
Relative Strength Index (RSI) | 53.28 |
Average Volume (20 Days) | 13,183 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Santhera Pharmaceuticals Holding AG had revenue of CHF 103.41 million and earned 54.78 million in profits. Earnings per share was 5.01.
Revenue | 103.41M |
Gross Profit | 100.18M |
Operating Income | 51.16M |
Pretax Income | 54.82M |
Net Income | 54.78M |
EBITDA | 53.76M |
EBIT | 51.16M |
Earnings Per Share (EPS) | 5.01 |
Balance Sheet
The company has 30.37 million in cash and 21.55 million in debt, giving a net cash position of 8.82 million or 0.75 per share.
Cash & Cash Equivalents | 30.37M |
Total Debt | 21.55M |
Net Cash | 8.82M |
Net Cash Per Share | 0.75 |
Equity (Book Value) | 59.94M |
Book Value Per Share | 5.30 |
Working Capital | -9.66M |
Cash Flow
In the last 12 months, operating cash flow was 47.27 million and capital expenditures -90,000, giving a free cash flow of 47.18 million.
Operating Cash Flow | 47.27M |
Capital Expenditures | -90,000 |
Free Cash Flow | 47.18M |
FCF Per Share | 4.03 |
Margins
Gross margin is 96.87%, with operating and profit margins of 49.47% and 52.97%.
Gross Margin | 96.87% |
Operating Margin | 49.47% |
Pretax Margin | 53.01% |
Profit Margin | 52.97% |
EBITDA Margin | 51.99% |
EBIT Margin | 49.47% |
FCF Margin | 45.62% |
Dividends & Yields
Santhera Pharmaceuticals Holding AG does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.42% |
Shareholder Yield | -0.42% |
Earnings Yield | 53.93% |
FCF Yield | 43.33% |
Stock Splits
The last stock split was on July 3, 2023. It was a reverse split with a ratio of 0.1.
Last Split Date | Jul 3, 2023 |
Split Type | Reverse |
Split Ratio | 0.1 |